Drug-target interaction prediction by random walk on the heterogeneous network.

Predicting potential drug-target interactions from heterogeneous biological data is critical not only for better understanding of the various interactions and biological processes, but also for the development of novel drugs and the improvement of human medicines. In this paper, the method of Network-based Random Walk with Restart on the Heterogeneous network (NRWRH) is developed to predict potential drug-target interactions on a large scale under the hypothesis that similar drugs often target similar target proteins and the framework of Random Walk. Compared with traditional supervised or semi-supervised methods, NRWRH makes full use of the tool of the network for data integration to predict drug-target associations. It integrates three different networks (protein-protein similarity network, drug-drug similarity network, and known drug-target interaction networks) into a heterogeneous network by known drug-target interactions and implements the random walk on this heterogeneous network. When applied to four classes of important drug-target interactions including enzymes, ion channels, GPCRs and nuclear receptors, NRWRH significantly improves previous methods in terms of cross-validation and potential drug-target interaction prediction. Excellent performance enables us to suggest a number of new potential drug-target interactions for drug development.

[1]  Yoshihiro Yamanishi,et al.  Supervised prediction of drug–target interactions using bipartite local models , 2009, Bioinform..

[2]  J. Lehár,et al.  Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.

[3]  Luhua Lai,et al.  Prediction of potential drug targets based on simple sequence properties , 2007, BMC Bioinformatics.

[4]  P. Robinson,et al.  Walking the interactome for prioritization of candidate disease genes. , 2008, American journal of human genetics.

[5]  Thomas Lengauer,et al.  A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.

[6]  S. Frantz Drug discovery: Playing dirty , 2005, Nature.

[7]  Yong Wang,et al.  Computationally Probing Drug-Protein Interactions Via Support Vector Machine , 2010 .

[8]  Xing Chen,et al.  A novel candidate disease genes prioritization method based on module partition and rank fusion. , 2010, Omics : a journal of integrative biology.

[9]  M S Waterman,et al.  Identification of common molecular subsequences. , 1981, Journal of molecular biology.

[10]  Jagdish Chandra Patra,et al.  Genome-wide inferring gene-phenotype relationship by walking on the heterogeneous network , 2010, Bioinform..

[11]  Elena Marchiori,et al.  Gaussian interaction profile kernels for predicting drug-target interaction , 2011, Bioinform..

[12]  David S. Wishart,et al.  DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..

[13]  Stuart L. Schreiber,et al.  Dissecting glucose signalling with diversity-oriented synthesis and small-molecule microarrays , 2002, Nature.

[14]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[15]  Antje Chang,et al.  New Developments , 2003 .

[16]  L. Lai,et al.  Finding multiple target optimal intervention in disease-related molecular network , 2008, Molecular systems biology.

[17]  Darren R. Flower,et al.  On the Properties of Bit String-Based Measures of Chemical Similarity , 1998, J. Chem. Inf. Comput. Sci..

[18]  S. Haggarty,et al.  Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays. , 2003, Chemistry & biology.

[19]  J. Drews Drug discovery: a historical perspective. , 2000, Science.

[20]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[21]  Weiming Yu,et al.  Predicting drug‐target interactions based on an improved semi‐supervised learning approach , 2011 .

[22]  Yoshihiro Yamanishi,et al.  Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework , 2010, Bioinform..

[23]  Yoshihiro Yamanishi,et al.  Prediction of drug–target interaction networks from the integration of chemical and genomic spaces , 2008, ISMB.

[24]  Kiyoko F. Aoki-Kinoshita,et al.  From genomics to chemical genomics: new developments in KEGG , 2005, Nucleic Acids Res..

[25]  Jürgen Bajorath,et al.  Combinatorial Preferences Affect Molecular Similarity/Diversity Calculations Using Binary Fingerprints and Tanimoto Coefficients , 2000, J. Chem. Inf. Comput. Sci..

[26]  J. Gies,et al.  Drugs and their molecular targets: an updated overview , 2008, Fundamental & clinical pharmacology.

[27]  M. Kanehisa,et al.  Development of a chemical structure comparison method for integrated analysis of chemical and genomic information in the metabolic pathways. , 2003, Journal of the American Chemical Society.

[28]  Xiaobo Zhou,et al.  Semi-supervised drug-protein interaction prediction from heterogeneous biological spaces , 2010, BMC Systems Biology.

[29]  Robert B. Russell,et al.  SuperTarget and Matador: resources for exploring drug-target relationships , 2007, Nucleic Acids Res..

[30]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.